Last reviewed · How we verify
MMF (Cellcept) and Steroids
MMF (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase to suppress T and B lymphocyte proliferation, while corticosteroids broadly suppress immune cell activation and inflammatory cytokine production.
MMF (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase to suppress T and B lymphocyte proliferation, while corticosteroids broadly suppress immune cell activation and inflammatory cytokine production. Used for Prevention of organ rejection in transplant recipients, Autoimmune and inflammatory conditions (e.g., lupus nephritis, vasculitis).
At a glance
| Generic name | MMF (Cellcept) and Steroids |
|---|---|
| Also known as | Prograf, CellCept |
| Sponsor | University of Luebeck |
| Drug class | Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid) |
| Target | IMPDH type II; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
MMF selectively inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes, thereby reducing their proliferation without affecting other cell types. Corticosteroids bind glucocorticoid receptors to suppress transcription of pro-inflammatory cytokines and adhesion molecules. Together, this combination provides potent immunosuppression used to prevent organ rejection and treat autoimmune conditions.
Approved indications
- Prevention of organ rejection in transplant recipients
- Autoimmune and inflammatory conditions (e.g., lupus nephritis, vasculitis)
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)
- Infection (bacterial, viral, fungal)
- Leukopenia
- Anemia
- Hypertension (steroid-related)
- Hyperglycemia (steroid-related)
- Tremor, headache
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMF (Cellcept) and Steroids CI brief — competitive landscape report
- MMF (Cellcept) and Steroids updates RSS · CI watch RSS
- University of Luebeck portfolio CI